NIOX GroupCSSPF 77 Return-on-Tangible-Equity is 5.82% as of Dec. 2025, which is 67% below its 10-year median of 17.82. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 760 Medical Devices & Instruments companies, NIOX Group ranks better than 82.63% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NIOX Group's annualized net income for the quarter that ended in Dec. 2025 was $2.95 Mil. NIOX Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $50.60 Mil. Therefore, NIOX Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 5.82%.
The historical rank and industry rank for NIOX Group's Return-on-Tangible-Equity or its related term are showing as below:
CSSPF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -166.55 Med: 17.82 Max: 46.33
Current: 19.66
During the past 13 years, NIOX Group's highest Return-on-Tangible-Equity was 46.33%. The lowest was -166.55%. And the median was 17.82%.
CSSPF's Return-on-Tangible-Equity is ranked better than 82.63% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs CSSPF: 19.66
NIOX Group (OTCPK:CSSPF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NIOX Group Return-on-Tangible-Equity Related Terms
NIOX Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NIOX Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, NIOX Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NIOX Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.82% mean?
NIOX Group (CSSPF) has a Return-on-Tangible-Equity of 5.82% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NIOX Group and its competitors. This is 67% below median its historical median of 17.82. According to the industry distribution chart, NIOX Group ranks #132 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 17.4%.
Is NIOX Group's Return-on-Tangible-Equity too high?
NIOX Group's current Return-on-Tangible-Equity of 5.82% is 67% below median its 10-year median of 17.82. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.12. NIOX Group's value of 5.82% is 41.4% above this industry median. Based on the distribution chart, NIOX Group ranks #132 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #132 out of 760 companies for Return-on-Tangible-Equity. This places NIOX Group in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.12. NIOX Group's value of 5.82% is 41.4% above this benchmark. While the company's 10-year median is 17.82 vs. the industry median of 4.12, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Return-on-Tangible-Equity of 5.82% is 41.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Return-on-Tangible-Equity is 5.82%, which is 67% below median its own 10-year median of 17.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current Return-on-Tangible-Equity is 5.82%, which is 67% below median its 10-year median of 17.82 and 41.4% above the Medical Devices & Instruments industry median of 4.12. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Return-on-Tangible-Equity is 5.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Return-on-Tangible-Equity: 5.82% (67% below median its 10-year median of 17.82)
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 41.4% above the Medical Devices & Instruments median (#132 of 760)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
